Minerva Neurosciences, Inc.

NASDAQ:NERV

Biotechnology

Healthcare
$2.18 -6.49%

-$0.30 today

Market cap
$108.64M
Beta
-0.11
P/E (TTM)
-0.2
EPS (TTM)
-$8.46
52W Low $1.76High $12.46

Volume 0.28M

Average 0.21M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$13.51B

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$74.45B

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.91M)(32.11M)(30.01M)1.44M(293.42M)
Depreciation & Amortization101.79K8.51K30.98K22.47K5.44M
Deferred Income Tax(1.8M)0000
Stock-Based Compensation5.22M4.11M1.97M1.33M1.33B
Change in Working Capital259.34K(4.06M)4.94M(320.6K)(632.35K)
Accounts Receivables00000
Inventory00000
Accounts Payables857.6K(883.55K)835.65K(197.48K)(1.06M)
Other Working Capital(598.27K)(3.18M)4.1M(123.13K)426.67K
Other Non-Cash Items21.53M7.41M8.28M(22.02M)(14.55B)
Operating Cash Flow(24.6M)(24.65M)(14.78M)(19.55M)(13.51B)
Capital Expenditures0(16.33K)000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow0(16.33K)000
Debt Repayment00000
Common Stock Issued0020M074.45M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities60M(5)(396.29K)074.38B
Financing Cash Flow60M(5)19.6M074.45B
Effect of Forex Changes00000
Net Change in Cash35.4M(24.66M)4.82M(19.55M)60.94B
Free Cash Flow(24.6M)(24.66M)(14.78M)(19.55M)(13.51B)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$293.4M
+ D&A$5.4M
+ Stock-Based Comp$1.3B
+ Deferred Tax$0
- Working Capital-$632.3K
- Other Non-Cash-$14.5B
= Operating Cash Flow-$13.5B
- Capex$0
= Free Cash Flow-$13.5B

Analysis

FY2025 free cash flow is -$13.5B. FCF conversion is 4604.6% of net income. Operating cash flow was -$13.5B, with capex of $0. The largest bridge item is Other Non-Cash at -$14.5B.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 6, 2026
10-QQuarterly reportNov 6, 2026
4Statement of changes in beneficial ownershipNov 3, 2026
SC 13GSC 13G filingOct 27, 2026

Does NERV generate free cash flow?

Minerva Neurosciences, Inc. (NERV) generated -$13.51B of free cash flow in fiscal 2025.

How much operating cash flow does NERV produce?

Operating cash flow was -$13.51B, before capital expenditures of $0.00.